Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Ryanair Holdings plc — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $76.8 (market cap $5.08B), while Ryanair Holdings plc trades at $51.96 (market cap $25.64B). The key difference: Ryanair Holdings plc is far larger — about 5× Oruka Therapeutics Inc. Common Stock's market cap, and Ryanair Holdings plc pays a 1.75% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Ryanair Holdings plc for 72 Days on average.
| ORKA | RYAAY | |
|---|---|---|
Market Cap | $5.08B | $25.64B |
Volume | 685,276 | 2,272,403 |
Sector | Health | Industrials |
52-Week High | $113.08 | $73.82 |
52-Week Low | $26.19 | $51.33 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $4.21B | $22.70B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ryanair Holdings (RYAAY) trades at $52.84, down 0.3% on the day, with a bearish technical signal despite attractive valuation metrics including a P/E of 12.86 and EV/EBITDA of 5.68. The company reported mixed Q2 2026 earnings with a slight miss on EPS expectations but maintains strong profitability with 12.13% net margins. Recent news highlights CEO commentary on potential airfare increases due to high oil prices and Boeing MAX 10 certification delays.
RYAAY presents a compelling value opportunity with strong fundamentals and analyst support (64.7% buy ratings), though near-term headwinds include fuel cost volatility and operational challenges. The stock's current bearish technical positioning near support levels may offer entry points for long-term investors seeking exposure to Europe's leading low-cost carrier.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
